Diagnostik, Verlauf und Therapie der autosomal 
dominanten polyzystischen Nierenerkrankung

Literatur
1 Grantham JJ, Torres VE, Chapman AB et al. Volume progression in polycystic kidney disease. N Engl J Med 2006; 354: 2122-2130
2 Haseebuddin M, Tanagho YS, Millar M et al. Long-term impact of laparoscopic cyst decortication on renal function, hypertension and pain control in patients with autosomal dominant polycystic kidney disease. J Urol 2012; 188: 1239-1244
3 Helal I, Reed B, McFann K et al. Glomerular hyperfiltration and renal progression in children with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011; 6: 2439-2443
4 Irazabal MV, Huston 3rd J, Kubly V et al. Extended follow-up of unruptured intracranial aneurysms detected by presymptomatic screening in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011; 6: 1274-1285
5 Jouret F, Lhommel R, Beguin C et al. Positron-emission computed tomography in cyst infection diagnosis in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011; 6: 1644-1650
6 Kühn EW, Walz G. Autosomal dominante polyzystische Nierenerkrankung. Dtsch Ärztebl 2007; 104: A3022-A3028
7 Li L, Szeto CC, Kwan BC et al. Peritoneal dialysis as the first-line renal replacement therapy in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2011; 57: 903-907
8 Masyuk TV, Masyuk AI, Torres VE et al. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. Gastroenterology 2007; 132: 1104-1116
9 Patch C, Charlton J, Roderick PJ et al. Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population-based study. Am J Kidney Dis 2011; 57: 856-862
10 Pei Y, Obaji J, Dupuis A et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol 2009; 20: 205-212
11 Serra AL, Poster D, Kistler AD et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363: 820-829
12 Torres VE, Chapman AB, Devuyst O et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367: 2407-2418
13 Torres VE, Chapman AB, Perrone RD et al. Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney Int 2012; 81: 577-585
14 van Keimpema L, Nevens F, Vanslembrouck R et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2009; 137: 1661-1668
15 Walz G, Budde K, Mannaa M et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363: 830-840